Loading stock data…
Recursion Pharmaceuticals (RXRX)
N/A
Market Closed
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Historical Price
No chart data available for RXRX
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.30M↓ | $35.35M↑ | $4.98M↓ | $19.10M↑ | $14.82M |
| Gross Profit | -$6.19M↓ | $21.08M↑ | -$9.70M↓ | -$1.06M↑ | -$7.01M |
| Operating Income | -$128.50M↓ | -$108.33M↑ | -$172.20M↑ | -$176.23M↑ | -$191.37M |
| Net Income | -$117.50M↓ | -$108.12M↑ | -$162.25M↑ | -$171.90M↑ | -$202.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.62%
Volume
Today's trading volume
-
Recent News
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
These aren't for the faint of heart.
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.
1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company
Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech sector.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.
X-Energy (XE) Powers 13.5% as Cathie Wood Gobbles More Stake
X-Energy Inc. (NASDAQ:XE) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants. X-Energy saw its share prices increase by 13.50 percent on Monday to end at $21.10 apiece, mirroring the broader market optimism and Cathie Wood’s increased exposure to its stock. Last week, Wood’s global asset management, ARK Invest, announced that […]